Artelo reported a net loss of $3.0 million, or $4.00 per share, for the quarter ended March 31, 2026, compared to a $2.4 million loss in Q1 2025. R&D expenses declined to $0.8 million from $1.4 million year-over-year, while G&A rose to $1.9 million from $1.0 million, and cash and investments totaled $10.3 million.

ART26.12 completed single ascending dose and food-effect cohorts with favorable safety and predictable pharmacokinetics. The company is preparing to launch the multiple ascending dose study in Q4 2026, targeting chemotherapy-induced peripheral neuropathy with a non-opioid, non-steroidal analgesic approach.

Interim Phase 2 CAReS data in cancer-related anorexia patients showed mean weight gain over 6% at the top dose versus 5% loss on placebo, along with increases in lean body mass and physical activity. Strategic discussions are underway for next-stage development and additional indications, including GLP-1 companion therapy and a funded glaucoma study.

A recent capital raise bolstered the balance sheet, extending runway to support key clinical milestones through 2027. The company benefits from third-party research grants, notably a fully funded ART27.13 glaucoma trial, and is engaged in partnering negotiations to drive future value creation.